<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Krieken, J.H.J.M. van</title>
    <link>http://repub.eur.nl/res/aut/356/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Inter-observer variation in the histological diagnosis of polyps in colorectal cancer screening (Article)</title>
      <link>http://repub.eur.nl/res/pub/25905/</link>
      <pubDate>2011-05-01T00:00:00Z</pubDate>
      <description>Aim: To determine the inter-observer variation in the histological diagnosis of colorectal polyps. Methods and results: Four hundred and forty polyps were randomly selected from a colorectal cancer screening programme. Polyps were first evaluated by a general (324 polyps) or expert (116 polyps) pathologist, and subsequently re-evaluated by an expert pathologist. Conditional agreement was reported, and inter-observer agreement was determined using kappa statistics. In 421/440 polyps (96%), agreement for their non-adenomatous or adenomatous nature was obtained, corresponding to a very good kappa value of 0.88. For differentiation of adenomas as non-advanced and advanced, consensus was obtained in 266/322 adenomas (83%), with a moderate kappa value of 0.58. For the non-adenomatous or adenomatous nature, both general and expert pathologists, and expert pathologists between each other, showed very good agreement {kappa values of 0.89 [95% confidence interval (CI) 0.83-0.95] and 0.86 (95% CI 0.73-0.98), respectively}. For categorization of adenomas as non-advanced and advanced, moderate agreement was found between general and expert pathologists, and between expert pathologists [kappa values of 0.56 (95% CI 0.44-0.67) and 0.64 (95% CI 0.43-0.85), respectively]. Conclusions: General and expert pathologists demonstrate very good inter-observer agreement for differentiating non-adenomas from adenomas, but only moderate agreement for non-advanced and advanced adenomas. The considerable variation in differentiating non-advanced and advanced adenomas suggests that more objective criteria are required for risk stratification in screening and surveillance guidelines. </description>
    </item> <item>
      <title>Inter-observer variation in the histological diagnosis of polyps in colorectal cancer screening (Article)</title>
      <link>http://repub.eur.nl/res/pub/26389/</link>
      <pubDate>2011-05-01T00:00:00Z</pubDate>
      <description>Aim: To determine the inter-observer variation in the histological diagnosis of colorectal polyps. Methods and results: Four hundred and forty polyps were randomly selected from a colorectal cancer screening programme. Polyps were first evaluated by a general (324 polyps) or expert (116 polyps) pathologist, and subsequently re-evaluated by an expert pathologist. Conditional agreement was reported, and inter-observer agreement was determined using kappa statistics. In 421/440 polyps (96%), agreement for their non-adenomatous or adenomatous nature was obtained, corresponding to a very good kappa value of 0.88. For differentiation of adenomas as non-advanced and advanced, consensus was obtained in 266/322 adenomas (83%), with a moderate kappa value of 0.58. For the non-adenomatous or adenomatous nature, both general and expert pathologists, and expert pathologists between each other, showed very good agreement {kappa values of 0.89 [95% confidence interval (CI) 0.83-0.95] and 0.86 (95% CI 0.73-0.98), respectively}. For categorization of adenomas as non-advanced and advanced, moderate agreement was found between general and expert pathologists, and between expert pathologists [kappa values of 0.56 (95% CI 0.44-0.67) and 0.64 (95% CI 0.43-0.85), respectively]. Conclusions: General and expert pathologists demonstrate very good inter-observer agreement for differentiating non-adenomas from adenomas, but only moderate agreement for non-advanced and advanced adenomas. The considerable variation in differentiating non-advanced and advanced adenomas suggests that more objective criteria are required for risk stratification in screening and surveillance guidelines. </description>
    </item> <item>
      <title>Recurrence and variability of germline EPCAM deletions in Lynch syndrome (Article)</title>
      <link>http://repub.eur.nl/res/pub/34227/</link>
      <pubDate>2011-04-01T00:00:00Z</pubDate>
      <description>Recently, we identified 3' end deletions in the EPCAM gene as a novel cause of Lynch syndrome. These truncating EPCAM deletions cause allele-specific epigenetic silencing of the neighboring DNA mismatch repair gene MSH2 in tissues expressing EPCAM. Here we screened a cohort of unexplained Lynch-like families for the presence of EPCAM deletions. We identified 27 novel independent MSH2-deficient families from multiple geographical origins with varying deletions all encompassing the 3' end of EPCAM, but leaving the MSH2 gene intact. Within The Netherlands and Germany, EPCAM deletions appeared to represent at least 2.8% and 1.1% of the confirmed Lynch syndrome families, respectively. MSH2 promoter methylation was observed in epithelial tissues of all deletion carriers tested, thus confirming silencing of MSH2 as the causative defect. In a total of 45 families, 19 different deletions were found, all including the last two exons and the transcription termination signal of EPCAM. All deletions appeared to originate from Alu-repeat mediated recombination events. In 17 cases regions of microhomology around the breakpoints were found, suggesting nonallelic homologous recombination as the most likely mechanism. We conclude that 3' end EPCAM deletions are a recurrent cause of Lynch syndrome, which should be implemented in routine Lynch syndrome diagnostics. </description>
    </item> <item>
      <title>Variation in lymph node evaluation in rectal cancer: A Dutch nationwide population-based study (Article)</title>
      <link>http://repub.eur.nl/res/pub/23551/</link>
      <pubDate>2011-01-01T00:00:00Z</pubDate>
      <description>Background: For adequate staging and subsequent accurate estimation of prognosis, a sufficient number of lymph nodes (LNs) has to be evaluated. This study aimed to identify factors associated with adequate nodal evaluation and to determine its relationship with survival. Methods: Data from all patients with stage I to III rectal carcinoma who underwent surgical treatment and who were diagnosed in the period 2000 to 2006 were retrieved from the Netherlands Cancer Registry. Multilevel logistic analysis was performed to examine the influence of relevant factors on the number of evaluated LNs. Kaplan-Meier and Cox regression analyses were used to analyze the association with overall survival. Results: The number of evaluated LNs was determined for 10,788 (91%) of 11,818 tumors. Median number of evaluated LNs was 7, ranging from 4 to 11 between pathology laboratories. The proportion of patients with positive LNs increased with increasing number of evaluated LNs. Men, younger patients, tumors with deeper invasion and nodal involvement, patients without preoperative radiotherapy who underwent a low anterior resection, and patients whose LNs were evaluated in an academic pathology laboratory were more likely to have ≥12 LNs evaluated. After adding these factors to the model, unexplained variation between pathology laboratories and between hospitals remained. The overall survival increased with increasing number of evaluated LNs. Conclusions: A large variation in LN evaluation among patients with rectal cancer was revealed. Improvement in LN evaluation by both hospitals and pathology laboratories could improve staging, leading to more reliable estimation of prognosis.</description>
    </item> <item>
      <title>Large variation between hospitals and pathology laboratories in lymph node evaluation in colon cancer and its impact on survival, a nationwide population based study in The Netherlands (Article)</title>
      <link>http://repub.eur.nl/res/pub/34106/</link>
      <pubDate>2011-01-01T00:00:00Z</pubDate>
      <description>Background: Adequate lymph node (LN) evaluation is important for planning treatment in patients with colon cancer. Aims of this study were to identify factors associated with adequate nodal examination and to determine its relationship with stage distribution and survival. Patients and methods: Data from patients with colon carcinoma stages I-III who underwent surgical treatment and diagnosed in the period 2000-2006 were retrieved from the Netherlands Cancer Registry. Multilevel logistic analysis was carried out to examine the influence of relevant factors on the number of evaluated LNs. The relationship with survival was analysed using Cox regression analysis. Results: The number of examined LN was determined for 30 682 of 33 206 tumours. Median number of evaluated LN was 8, ranging from 4 to 15 between pathology laboratories. Females, younger patients, right-sided pN+ tumours with higher pT stage and patients diagnosed in an academic centre were less likely to have nine or less LN evaluated. Unexplained variation between hospitals and pathology laboratories remained, leading to differences in stage distribution. With increasing number of evaluated LN, the risk of death decreased. Conclusion: There was large diversity in nodal examination among patients with colon cancer, leading to differences in stage distribution and being associated with survival. </description>
    </item> <item>
      <title>Overlap, common features, and essential differences in pediatric granulomatous inflammatory bowel disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/27863/</link>
      <pubDate>2010-12-01T00:00:00Z</pubDate>
      <description>Overlap in the clinical presentation of pediatric granulomatous inflammatory bowel disease may be substantial, depending on the mode of presentation. Chronic granulomatous disease (CGD) may present with granulomatous colitis, perianal abscesses, hepatic abscesses or granulomas, failure to thrive, and obstruction of the gastrointestinal tract (including esophageal strictures and dysmotility, delayed gastric emptying, and small bowel obstruction). Anemia, thrombocytosis, elevated C-reactive protein and erythrocyte sedimentation rate, and hypoalbuminemia are nonspecific and may occur in any of the granulomatous inflammatory bowel diseases. In histology, macrophages with cytoplasmic inclusions will be rather specific for CGD. Sarcoidosis may present with abdominal pain or discomfort, diarrhea, weight loss, growth failure, delayed puberty, erythema nodosum, arthritis, uveitis, and hepatic granulomata. Only in 55% of the patients will angiotensin-converting enzyme be elevated. The noncaseating epithelioid granulomata will be unspecific. Bronchoalveolar lymphocytosis and abnormalities in pulmonary function are reported in sarcoidosis and in Crohn disease (CD) and CGD. Importantly, patients with CD may present with granulomatous lung disease, fibrosing alveolitis, and drug-induced pneumonitis. Sarcoidosis and concomitant gastrointestinal CD have been reported in patients, as well as coexistence of CD and sarcoidosis in siblings. Common susceptibility loci have been identified in CD and sarcoidosis. CD and CGD share defects in the defense mechanisms against different microbes. In the present review, common features and essential differences are discussed in clinical presentation and diagnostics-including histology-in CGD, sarcoidosis, and CD, together with 2 other granulomatous inflammatory bowel diseases, namely abdominal tuberculosis and Hermansky-Pudlak syndrome. Instructions for specific diagnosis and respective treatments are provided. Copyright </description>
    </item> <item>
      <title>Variation in Lymph Node Evaluation in Rectal Cancer: A Dutch Nationwide Population-Based Study (Article)</title>
      <link>http://repub.eur.nl/res/pub/20938/</link>
      <pubDate>2010-01-01T00:00:00Z</pubDate>
      <description>Background: For adequate staging and subsequent accurate estimation of prognosis, a sufficient number of lymph nodes (LNs) has to be evaluated. This study aimed to identify factors associated with adequate nodal evaluation and to determine its relationship with survival. Methods: Data from all patients with stage I to III rectal carcinoma who underwent surgical treatment and who were diagnosed in the period 2000 to 2006 were retrieved from the Netherlands Cancer Registry. Multilevel logistic analysis was performed to examine the influence of relevant factors on the number of evaluated LNs. Kaplan-Meier and Cox regression analyses were used to analyze the association with overall survival. Results: The number of evaluated LNs was determined for 10,788 (91%) of 11,818 tumors. Median number of evaluated LNs was 7, ranging from 4 to 11 between pathology laboratories. The proportion of patients with positive LNs increased with increasing number of evaluated LNs. Men, younger patients, tumors with deeper invasion and nodal involvement, patients without preoperative radiotherapy who underwent a low anterior resection, and patients whose LNs were evaluated in an academic pathology laboratory were more likely to have ≥12 LNs evaluated. After adding these factors to the model, unexplained variation between pathology laboratories and between hospitals remained. The overall survival increased with increasing number of evaluated LNs. Conclusions: A large variation in LN evaluation among patients with rectal cancer was revealed. Improvement in LN evaluation by both hospitals and pathology laboratories could improve staging, leading to more reliable estimation of prognosis.</description>
    </item> <item>
      <title>Risk of Developing Adenomas and Carcinomas in the Ileal Pouch in Patients With Familial Adenomatous Polyposis (Article)</title>
      <link>http://repub.eur.nl/res/pub/14417/</link>
      <pubDate>2008-11-01T00:00:00Z</pubDate>
      <description>Background &amp; Aims: At present, more than half of patients with familial adenomatous polyposis (FAP) are treated with a proctocolectomy and an ileal pouch-anal anastomosis (IPAA). Originally it was thought that this procedure would eliminate the risk of developing rectal cancer. However, an increasing number of studies reported development of adenoma and carcinoma in the pouch. The aim of this study was to evaluate the long-term risk of developing adenomas and carcinomas in the pouch in a large cohort of Dutch FAP patients. Methods: A total of 254 patients with FAP who underwent an IPAA were selected from the Dutch Polyposis Registry. The results of the surveillance examinations and the pathology reports were analyzed. Surveillance with chromoendoscopy was offered to a subgroup of patients. Results: Full information on follow-up was available in 212 (84%) patients. These patients (56% male) underwent a total of 761 endoscopies. The mean follow-up was 7.9 years (range, 0.4-20.3 years). The cumulative risk of developing an adenoma in the pouch at 10-year follow-up was 45%. Twenty-five patients (11.8%) developed an adenoma with advanced pathology, and 4 (1.9%) developed a carcinoma. The cumulative risk of developing a pouch carcinoma at 10-year follow-up was 1%. A very high prevalence (75.7%) of adenomas was found in a subgroup of patients who were examined with chromoendoscopy. Conclusions: This study demonstrated that although the risk of developing adenomas in the pouch after an IPAA is high, the risk of malignant degeneration appears to be low. The use of chromoendoscopy improves the detection of small adenomas.</description>
    </item> <item>
      <title>Unique morphological spectrum of lymphomas in Nijmegen breakage syndrome (NBS) patients with high frequency of consecutive lymphoma formation (Article)</title>
      <link>http://repub.eur.nl/res/pub/14424/</link>
      <pubDate>2008-11-01T00:00:00Z</pubDate>
      <description>Nijmegen breakage syndrome (NBS) is an autosomal recessive disorder characterized by microcephaly, immunodeficiency, radiation hypersensitivity, chromosomal instability and increased incidence of malignancies. In Poland 105 NBS cases showing mutations in the NBS gene (nibrin, NBN), have been diagnosed, ∼53% of which have developed cancer, mainly (&gt;90%) lymphoid malignancies. This study is based upon the largest reported group of NBS-associated lymphomas. The predominant lymphoma types found in these 14 NBS children were diffuse large B cell lymphoma (DLBCL) and T cell lymphoblastic lymphoma (T-LBL/ALL), all showing monoclonal Ig/TCR rearrangements. The spectrum of NBS lymphomas is completely different from sporadic paediatric lymphomas and lymphomas in other immunodeficient patients. Morphological and molecular analysis of consecutive lymphoproliferations in six NBS patients revealed two cases of true secondary lymphoma. Furthermore, 9/13 NBS patients with lymphomas analysed by split-signal FISH showed breaks in the Ig or TCR loci, several of which likely represent chromosome aberrations. The combined data would fit a model in which an NBN gene defect results in a higher frequency of DNA misrejoining during double-strand break (DSB) repair, thereby contributing to an increased likelihood of lymphoma formation in NBS patients.</description>
    </item> <item>
      <title>Pitfalls in TCR gene clonality testing: teaching cases (Article)</title>
      <link>http://repub.eur.nl/res/pub/15977/</link>
      <pubDate>2008-08-26T00:00:00Z</pubDate>
      <description>Clonality testing in T-lymphoproliferations has technically become relatively easy to perform in routine laboratories using standardized multiplex polymerase chain reaction protocols for T-cell receptor (TCR) gene analysis as developed by the BIOMED-2 Concerted Action BMH4-CT98-3936. Expertise with clonality diagnostics and knowledge about the biology of TCR gene recombination are essential for correct interpretation of TCR clonality data. Several immunobiological and technical pitfalls that should be taken into account to avoid misinterpretation of data are addressed in this report. Furthermore, we discuss the need to integrate the molecular data with those from immunohistology, and preferably also flow cytometric immunophenotyping, for appropriate interpretation. Such an interactive, multidisciplinary diagnostic model guarantees integration of available data to reach the most reliable diagnosis.</description>
    </item> <item>
      <title>Immunoglobulin/T-cell receptor clonality diagnostics (Article)</title>
      <link>http://repub.eur.nl/res/pub/37102/</link>
      <pubDate>2007-12-01T00:00:00Z</pubDate>
      <description>Clonality testing in lymphoid malignancies has become technically relatively easy to perform in routine laboratories using standardized multiplex polymerase chain reaction protocols for Ig/T-cell receptor (TCR) gene analysis. Expertise with clonality diagnostics and knowledge about the biology of Ig/TCR recombination are essential for correct interpretation of the Ig/TCR clonality data. Several immunobiologic and technical pitfalls that should be taken into account to avoid misinterpretation of data are addressed in this review. Furthermore, the need to integrate the molecular data with that from (hemato-)pathology, and preferably also flowcytometric immunophenotyping for appropriate interpretation, is discussed. Such an interactive, multidisciplinary diagnostic model guarantees integration of all available data to reach the most reliable diagnosis. </description>
    </item> <item>
      <title>Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan® predicts the absence of significant liver fibrosis (Article)</title>
      <link>http://repub.eur.nl/res/pub/36909/</link>
      <pubDate>2007-06-01T00:00:00Z</pubDate>
      <description>Background: Methotrexate (MTX) use is associated with hepatic fibrosis in psoriasis patients. To monitor this serial liver biopsies were performed. The Fibroscan® and the Fibrotest are two novel, non-invasive methods that might be able to assess MTX-induced hepatic fibrosis. Aim: Evaluating the accuracy and feasibility of the Fibroscan® and Fibrotest to detect significant MTX-induced liver fibrosis in psoriasis patients. Methods: We assessed 24 psoriasis patients who had a recent liver biopsy during MTX use. The results from the Fibroscan® and Fibrotest were compared with liver histology. Results: Fibroscan® values (n=20) ranged between 3.3 and 18.4kPa (median value 6.4kPa) and correctly identified 88% of the patients without significant liver fibrosis (Metavir score &lt;F2, Fibroscan® ≤7.1kPa). The Fibrotest identified 83% of the patients with significant liver fibrosis (Metavir score ≥F2, Fibrotest &gt;0.31). Conclusion: In this population, Fibrotest accurately predicted the presence of significant liver fibrosis while the Fibroscan® accurately predicted the absence of significant liver fibrosis in MTX users. This suggests that a combination of Fibrotest and Fibroscan® should prospectively be evaluated in monitoring and detecting significant MTX-induced liver fibrosis in psoriasis patients. </description>
    </item> <item>
      <title>Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: Usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936 (Article)</title>
      <link>http://repub.eur.nl/res/pub/36317/</link>
      <pubDate>2007-02-01T00:00:00Z</pubDate>
      <description>Lymphoproliferations are generally diagnosed via histomorphology and immunohistochemistry. Although mostly conclusive, occasionally the differential diagnosis between reactive lesions and malignant lymphomas is difficult. In such cases molecular clonality studies of immunoglobulin (Ig)/T-cell receptor (TCR) rearrangements can be useful. Here we address the issue of clonality assessment in 106 histologically defined reactive lesions, using the standardized BIOMED-2 Ig/TCR multiplex polymerase chain reaction (PCR) heteroduplex and GeneScan assays. Samples were reviewed nationally, except 10% random cases and cases with clonal results selected for additional international panel review. In total 75% (79/106) only showed polyclonal Ig/TCR targets (type I), whereas another 15% (16/106) represent probably polyclonal cases, with weak Ig/TCR (oligo)clonality in an otherwise polyclonal background (type II). Interestingly, in 10% (11/106) clear monoclonal Ig/ TCR products were observed (types III/IV), which prompted further pathological review. Clonal cases included two missed lymphomas in national review and nine cases that could be explained as diagnostically difficult cases or probable lymphomas upon additional review. Our data show that the BIOMED-2 Ig/TCR multiplex PCR assays are very helpful in confirming the polyclonal character in the vast majority of reactive lesions. However, clonality detection in a minority should lead to detailed pathological review, including close interaction between pathologist and molecular biologist.</description>
    </item> <item>
      <title>Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936 (Article)</title>
      <link>http://repub.eur.nl/res/pub/36320/</link>
      <pubDate>2007-02-01T00:00:00Z</pubDate>
      <description>Polymerase chain reaction (PCR) assessment of clonal immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements is an important diagnostic tool in mature B-cell neoplasms. However, lack of standardized PCR protocols resulting in a high level of false negativity has hampered comparability of data in previous clonality studies. In order to address these problems, 22 European laboratories investigated the Ig/TCR rearrangement patterns as well as t(14;18) and t(11;14) translocations of 369 B-cell malignancies belonging to five WHO-defined entities using the standardized BIOMED-2 multiplex PCR tubes accompanied by international pathology panel review. B-cell clonality was detected by combined use of the IGH and IGK multiplex PCR assays in all 260 definitive cases of B-cell chronic lymphocytic leukemia (n = 56), mantle cell lymphoma (n = 54), marginal zone lymphoma (n = 41) and follicular lymphoma (n = 109). Two of 109 cases of diffuse large B-cell lymphoma showed no detectable clonal marker. The use of these techniques to assign cell lineage should be treated with caution as additional clonal TCR gene rearrangements were frequently detected in all disease categories. Our study indicates that the BIOMED-2 multiplex PCR assays provide a powerful strategy for clonality assessment in B-cell malignancies resulting in high Ig clonality detection rates particularly when IGH and IGK strategies are combined.</description>
    </item> <item>
      <title>Improved reliability of lymphoma diagnostics via PCR-based clonality testing: - Report of the BIOMED-2 Concerted Action BHM4-CT98-3936 (Article)</title>
      <link>http://repub.eur.nl/res/pub/36333/</link>
      <pubDate>2007-02-01T00:00:00Z</pubDate>
      <description>The diagnosis of malignant lymphoma is a recognized difficult area in histopathology. Therefore, detection of clonality in a suspected lymphoproliferation is a valuable diagnostic criterion. We have developed primer sets for the detection of rearrangements in the B- and T-cell receptor genes as reliable tools for clonality assessment in lymphoproliferations suspected for lymphoma. In this issue of Leukemia, the participants of the BIOMED-2 Concerted Action CT98-3936 report on the validation of the newly developed clonality assays in various disease entities. Clonality was detected in 99% of all B-cell malignancies and in 94% of all T-cell malignancies, whereas the great majority of reactive lesions showed polyclonality. The combined BIOMED-2 results are summarized in a guideline, which can now be implemented in routine lymphoma diagnostics. The use of this standardized approach in patients with a suspect lymphoproliferation will result in improved diagnosis of malignant lymphoma.</description>
    </item> <item>
      <title>Enhanced expression of fibroblast growth factors and receptor FGFR-1 during vascular remodeling in chronic obstructive pulmonary disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/10000/</link>
      <pubDate>2002-01-01T00:00:00Z</pubDate>
      <description>Important characteristics of chronic obstructive pulmonary disease (COPD)
      include airway and vascular remodeling, the molecular mechanisms of which
      are poorly understood. We assessed the role of fibroblast growth factors
      (FGF) in pulmonary vascular remodeling by examining the expression pattern
      of FGF-1, FGF-2, and the FGF receptor (FGFR-1) in peripheral area of lung
      tissues from patients with COPD (FEV(1) &lt; or = 75%; n = 15) and without
      COPD (FEV(1) &gt; or = 85%; n = 13). Immunohistochemical staining results
      were evaluated by digital video image analysis as well as by manual
      scoring. FGF-1 and FGFR-1 were detected in vascular smooth muscle (VSM),
      airway smooth muscle, and airway epithelial cells. FGF-2 was localized in
      the cytoplasm of airway epithelium and in the nuclei of airway smooth
      muscle, VSM, and endothelial cells. In COPD cases, an unequivocal increase
      in FGF-2 expression was observed in VSM (3-fold, P = 0.001) and
      endothelium (2-fold, P = 0.007) of small pulmonary vessels with a luminal
      diameter under 200 micro m. In addition, FGFR-1 levels were elevated in
      the intima (1.5-fold, P = 0.05). VSM cells of large (&gt; 200 micro m)
      pulmonary vessels showed increased staining for FGF-1 (1.6-fold, P &lt; 0.03)
      and FGFR-1 (1.4-fold, P &lt; 0.04) in COPD. Pulmonary vascular remodeling,
      assessed as the ratio of alpha-smooth muscle actin staining and vascular
      wall area with the lumen diameter, was increased in large vessels of
      patients with COPD (P = 0.007) and was inversely correlated with FEV(1)
      values (P &lt; 0.007). Our results suggest an autocrine role of the
      FGF-FGFR-1 system in the pathogenesis of COPD-associated vascular
      remodeling.</description>
    </item> <item>
      <title>The role of molecular analysis of immunoglobulin and T cell receptor gene rearrangements in the diagnosis of lymphoproliferative disorders (Article)</title>
      <link>http://repub.eur.nl/res/pub/9666/</link>
      <pubDate>2001-01-01T00:00:00Z</pubDate>
      <description>AIMS: To investigate whether the analysis of immunoglobulin (Ig)/T cell
          receptor (TCR) rearrangements is useful in the diagnosis of
          lymphoproliferative disorders. METHODS: In a series of 107 consecutive
          cases with initial suspicion of non-Hodgkin's lymphoma (NHL), Southern
          blot (SB) analysis of Ig/TCR rearrangements was performed. RESULTS: In 98
          of 100 histopathologically conclusive cases, Ig/TCR gene results were
          concordant. In one presumed diffuse large B cell lymphoma (DLCL) and one
          follicular lymphoma (FL) case no clonality could be detected by SB
          analysis, or by polymerase chain reaction (PCR) at second stage. In the
          DLCL, sampling error might have occurred; the FL was revised after an
          initial diagnosis of reactivity. In many of the histopathologically
          inconclusive cases Ig/TCR gene SB analysis was helpful, giving support for
          the histopathological suspicion. However, because of a lack of (clinical)
          follow up data this could not be confirmed in a few cases. CONCLUSIONS:
          Experienced haematopathologists or a pathologist panel can diagnose
          malignant versus reactive lesions in most cases without the need for
          Ig/TCR gene analysis and can select the 5-10% of cases that might benefit
          from molecular clonality studies.</description>
    </item>
  </channel>
</rss>